Andrew Quon, MD
Nuclear Medicine · Encino
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 11
Offices
11 locations · Regents of the University of California · The Regents of the University of California
Hospitals listed: Ronald Reagan UCLA Medical Center · Santa Monica - UCLA Med Ctr & Orthopaedic Hospital · UCLA West Valley Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Quon’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A70244 · Current
Licensed to practise in California · since 1999 · expires 2027-11-30 · University of Texas Southwestern Medical School at Dallas.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Ronald Reagan UCLA Medical CenterLos Angeles, CAAcute Care Hospital · Government - State · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of Jonsson Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 6.27 (4.69 to 7.85) · 3,570 cases, Jul 2022 – Jun 2024Better than the national rate — Postoperative respiratory failure rate: 5.17 (1.78 to 8.56) · 1,778 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.21 (0 to 0.62) · 8,165 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.59, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.611, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.503, Oct 2024 – Sep 2025
- Santa Monica - UCLA Med Ctr & Orthopaedic HospitalSanta Monica, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsPatients rate it 3 of 5 · 75% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Pressure ulcer rate: 0.09 (0 to 0.59) · 6,805 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.667, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.6 to 1) · 1,274 cases, Jan 2024 – Dec 2024
- UCLA West Valley Medical CenterWest Hills, CAAcute Care Hospital · Proprietary · Has an emergency departmentPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 1 of 5 · 53% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.454, Oct 2024 – Sep 2025
See every measure and the patient survey for Ronald Reagan UCLA Medical Center
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 6.27 (4.69 to 7.85) · 3,570 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 5.17 (1.78 to 8.56) · 1,778 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.21 (0 to 0.62) · 8,165 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.59 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.611 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.503 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.67 (0 to 1.44) · 2,883 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.9 (0.7 to 1.09) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 171.14 (139.88 to 202.41) · 282 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.1 · 122 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 49 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.5 · 107 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 350 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.1 · 436 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.8 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.4 · 3,004 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 9,102 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.09 to 0.44) · 10,460 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.67 (0.57 to 2.77) · 1,972 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.27 to 3.44) · 3,000 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.93 (3.76 to 8.09) · 2,101 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.65 (1.31 to 3.98) · 1,032 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.56 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.626 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.8 · 138 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 357 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -7.1 · 122 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -12.9 · 385 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 13.6 · 427 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 404 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.7 to 6.5) · 609 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.3 (10.1 to 15) · 609 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.8 · 119 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 10.8 (8.5 to 13.7) · 2,701 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,463 cases | No different | Jan 2024 – Dec 2024 |
What patients said (814 patients answered, 18% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Santa Monica - UCLA Med Ctr & Orthopaedic Hospital
Behind the star rating — Deaths: 3 better, 4 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 7 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Pressure ulcer rateComplications and deaths | 0.09 (0 to 0.59) · 6,805 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.667 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.6 to 1) · 1,274 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.87 (0 to 1.75) · 1,532 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.76 to 1.31) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.96 (97.85 to 194.07) · 118 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 87 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.4 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.1 · 295 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 9.4 · 497 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.7 · 100 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 2,432 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.39) · 7,694 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.07 to 0.44) · 8,081 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.95 (3.16 to 6.74) · 1,949 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.82 (0.22 to 3.41) · 915 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.63 (0.18 to 3.08) · 1,832 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.05 (4.53 to 17.57) · 886 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.16 (5.05 to 11.26) · 893 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.62 (0.15 to 3.09) · 396 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 336 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.902 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.479 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.612 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.274 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.5 · 99 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.5 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 57.2 · 67 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 386 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 41.3 · 584 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.7 · 605 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.7 (3.1 to 7.3) · 81 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.5 (7.5 to 14.8) · 81 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 304 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.2 (9.5 to 15.5) · 1,955 cases | No different | Jan 2022 – Dec 2024 |
What patients said (639 patients answered, 19% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 75% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for UCLA West Valley Medical Center
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 0 better, 5 the same, 3 worse of 8 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.454 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.87 (0 to 1.86) · 925 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.74 to 1.41) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 126.11 (75.24 to 176.99) · 66 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.4 · 29 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 78 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11 · 179 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.9 · 310 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.3 · 499 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.8 · 187 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 2,150 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.36) · 5,783 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.29 (0.09 to 0.48) · 5,787 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.94 (1.81 to 6.06) · 1,083 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.21) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.83 (0.29 to 3.36) · 1,048 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 14.62 (6.73 to 22.51) · 354 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.07 (1.14 to 9) · 319 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 221 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.46 (0 to 1.09) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.457 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.124 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.781 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.838 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 201 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.8 · 400 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 5.5 · 173 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.2 · 369 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 51.5 · 534 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.5 · 569 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.8 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 105 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (9.3 to 17.4) · 30 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.5) · 136 cases | No different | Jan 2024 – Dec 2024 |
What patients said (519 patients answered, 17% of those asked)
| Cleanliness | 2 |
| Nurse communication | 1 |
| Doctor communication | 1 |
| Communication about medicines | 1 |
| Discharge information | 2 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 62% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 67% |
| Staff "always" explained | 49% |
| Yes, staff "did" give patients this information | 80% |
| Yes, staff "did" give patients information about help after discharge | 78% |
| Doctors "always" explained things so they could understand | 64% |
| Doctors "always" listened carefully | 64% |
| Doctors "always" treated them with courtesy and respect | 73% |
| Patients who gave a rating of "9" or "10" (high) | 52% |
| Staff "always" explained new medications | 64% |
| Nurses "always" explained things so they could understand | 67% |
| Nurses "always" listened carefully | 66% |
| Nurses "always" treated them with courtesy and respect | 74% |
| "Always" quiet at night | 39% |
| "YES", patients would definitely recommend the hospital | 53% |
| Staff "always" explained possible side effects | 35% |
| Yes, staff "did" give patients information about possible symptoms | 81% |
Original Medicare doctor bills
$183,455
Medicare paid this office $183,455 for 1,290 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Piflufolastat f-18, diagnostic, 1 millicurie | 15 | $72,495 | $514 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 277 | $27,103 | $95 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 46 | $18,166 | $395 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 47 | $7,164 | $76 |
| Dxa bone density measurement of hip, pelvis, spine | 634 | $6,566 | $10 |
See all 15 services
| Piflufolastat f-18, diagnostic, 1 millicurie | 15 | $72,495 | $514 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 277 | $27,103 | $95 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 46 | $18,166 | $395 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 47 | $7,164 | $76 |
| Dxa bone density measurement of hip, pelvis, spine | 634 | $6,566 | $10 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 17 | $5,402 | $300 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 53 | $3,356 | $63 |
| Dxa bone density measurement of hip, pelvis, spine | 74 | $3,249 | $44 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 50 | $2,277 | $42 |
| Nuclear medicine study of brain with metabolic evaluation | 19 | $1,105 | $53 |
| Nuclear medicine study of bone and/or joint whole body | 17 | $628 | $35 |
| Nuclear medicine study of lymphatic system | 11 | $532 | $48 |
| Nuclear medicine study of lung ventilation and circulation | 12 | $522 | $44 |
| Nuclear medicine study of lung circulation | 13 | $392 | $30 |
| Dxa bone density measurement of forearm, finger, hand, or foot | 15 | $155 | $10 |
Who their Medicare patients are
1,290 Original Medicare patients in 2024. Average age 74 · Under 65 4% · 85 and older 10% · Women 66% · Also on Medicaid 19% · Health risk score 1.53. At or below the middle of the specialty; the typical nuclear medicine clinician is at 1.94.
Conditions among them: High blood pressure 64% · Cancer 33% · Coronary heart disease 31% · Diabetes 26% · Depression 23% · Chronic kidney disease 19% · Heart failure 15% · Atrial fibrillation 15% · COPD 14% · Stroke 7% · Dementia 6%.
The office billed $1,811,444, Medicare allowed $228,137 and paid $183,455; for 2,288 services of 39 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,290 | 2,288 | 74 | 1.53 | $1,811,444 | $183,455 |
| 2023 | 1,178 | 1,692 | 74 | 1.55 | $1,424,416 | $141,413 |
| 2022 | 1,269 | 1,543 | 74 | 1.55 | $1,428,769 | $125,513 |
| 2021 | 1,573 | 2,026 | 73 | 1.48 | $1,314,558 | $112,108 |
| 2020 | 1,204 | 1,774 | 73 | 1.69 | $1,197,424 | $103,762 |
| 2019 | 1,163 | 1,899 | 74 | 1.63 | $1,619,396 | $148,332 |
| 2018 | 1,299 | 1,568 | 73 | 1.56 | $1,738,013 | $151,442 |
| 2017 | 952 | 1,321 | 73 | 1.81 | $1,082,120 | $122,718 |
| 2016 | 1,082 | 1,259 | 72 | 1.77 | $679,069 | $95,833 |
| 2015 | 1,269 | 1,453 | 72 | 1.86 | $505,417 | $87,722 |
| 2014 | 989 | 1,121 | 71 | 1.81 | $391,016 | $66,675 |
| 2013 | 891 | 999 | 71 | 1.79 | $323,925 | $53,774 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 14 services
| Piflufolastat f-18, diagnostic, 1 millicurie | 11 | $50,401 | $489 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 253 | $25,206 | $94 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 31 | $12,034 | $388 |
| Dxa bone density measurement of hip, pelvis, spine | 595 | $5,986 | $10 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 31 | $4,725 | $76 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 13 | $3,701 | $285 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 50 | $3,034 | $59 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 53 | $2,384 | $40 |
| Dxa bone density measurement of hip, pelvis, spine | 29 | $1,287 | $44 |
| Nuclear medicine study of bone and/or joint whole body | 23 | $821 | $34 |
| Nuclear medicine study of lymphatic system | 14 | $663 | $47 |
| Nuclear medicine study of stomach to assess emptying | 16 | $506 | $32 |
| Dxa bone density measurement of forearm, finger, hand, or foot | 38 | $397 | $10 |
| Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | 12 | $187 | $16 |
2022: 15 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 88 | $37,088 | $421 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 192 | $18,660 | $96 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 88 | $15,565 | $89 |
| Dxa bone density measurement of hip, pelvis, spine | 600 | $6,225 | $10 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 88 | $5,470 | $62 |
| Dxa bone density measurement of hip, pelvis, spine | 106 | $4,624 | $44 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 14 | $4,027 | $288 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 35 | $1,834 | $42 |
| Radioactive drug therapy through a vein | 11 | $1,071 | $82 |
| Nuclear medicine study of bone and/or joint whole body | 26 | $964 | $32 |
| Nuclear medicine study of lymphatic system | 13 | $584 | $45 |
| Nuclear medicine study of lung ventilation and circulation | 13 | $551 | $39 |
| Nuclear medicine study of lung circulation | 18 | $550 | $29 |
| Nuclear medicine study of stomach to assess emptying | 12 | $391 | $33 |
| Dxa bone density measurement of forearm, finger, hand, or foot | 29 | $313 | $11 |
2021: 14 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 251 | $25,629 | $95 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 46 | $20,866 | $454 |
| Dxa bone density measurement of hip, pelvis, spine | 792 | $8,371 | $11 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 46 | $8,256 | $90 |
| Dxa bone density measurement of hip, pelvis, spine | 120 | $5,366 | $45 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 77 | $4,891 | $64 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 13 | $3,607 | $277 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 54 | $2,579 | $38 |
| Nuclear medicine study of bone and/or joint whole body | 71 | $2,413 | $34 |
| Nuclear medicine study of lymphatic system | 19 | $893 | $47 |
| Nuclear medicine study of lung circulation | 28 | $840 | $30 |
| Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | 12 | $740 | $62 |
| Dxa bone density measurement of forearm, finger, hand, or foot | 46 | $506 | $11 |
| Nuclear medicine study of stomach to assess emptying | 14 | $399 | $29 |
2020: 15 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 56 | $23,320 | $416 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 155 | $15,497 | $93 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 57 | $9,559 | $84 |
| Dxa bone density measurement of hip, pelvis, spine | 207 | $9,417 | $45 |
| Dxa bone density measurement of hip, pelvis, spine | 485 | $5,212 | $11 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 70 | $4,679 | $67 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 14 | $2,980 | $199 |
| Nuclear medicine study of bone and/or joint whole body | 70 | $2,518 | $35 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 28 | $1,736 | $46 |
| Radioactive drug therapy through a vein | 11 | $1,202 | $86 |
| Nuclear medicine study of lymphatic system | 18 | $861 | $48 |
| Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | 12 | $739 | $62 |
| Dxa bone density measurement of forearm, finger, hand, or foot | 15 | $556 | $37 |
| Nuclear medicine study of lung circulation | 16 | $508 | $32 |
| Dxa bone density measurement of forearm, finger, hand, or foot | 22 | $246 | $11 |
2019: 14 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 85 | $37,538 | $442 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 19 | $26,481 | $1,394 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 183 | $19,331 | $100 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 86 | $14,765 | $86 |
| Dxa bone density measurement of hip, pelvis, spine | 215 | $9,916 | $46 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 24 | $4,782 | $199 |
| Dxa bone density measurement of hip, pelvis, spine | 420 | $4,495 | $11 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 68 | $4,473 | $66 |
| Nuclear medicine study of bone and/or joint whole body | 48 | $1,515 | $32 |
| Nuclear medicine study of parathyroid with spect | 15 | $716 | $48 |
| Nuclear medicine study of lymphatic system | 14 | $663 | $47 |
| Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | 11 | $653 | $59 |
| Nuclear medicine study of liver | 14 | $523 | $29 |
| Dxa bone density measurement of forearm, finger, hand, or foot | 23 | $256 | $11 |
2018: 13 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 90 | $40,657 | $452 |
| Nuclear medicine study of brain with metabolic evaluation | 19 | $25,310 | $1,332 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 220 | $22,516 | $94 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 87 | $15,068 | $87 |
| Dxa bone density measurement of hip, pelvis, spine | 251 | $12,033 | $48 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 27 | $5,292 | $196 |
| Dxa bone density measurement of hip, pelvis, spine | 456 | $4,988 | $11 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 49 | $3,117 | $64 |
| Nuclear medicine study of bone and/or joint whole body | 48 | $1,747 | $34 |
| Nuclear medicine study of brain with metabolic evaluation | 23 | $919 | $40 |
| Nuclear medicine study of lymphatic system | 17 | $701 | $41 |
| Nuclear medicine study of liver | 14 | $485 | $27 |
| Nuclear medicine study of lung circulation | 13 | $393 | $30 |
2017: 13 services
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 87 | $38,714 | $445 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 179 | $17,929 | $97 |
| Nuclear medicine study of brain with metabolic evaluation | 14 | $17,811 | $1,272 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 87 | $15,068 | $87 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 71 | $4,665 | $66 |
| Dxa bone density measurement of hip, pelvis, spine | 69 | $3,204 | $46 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 16 | $3,136 | $196 |
| Dxa bone density measurement of hip, pelvis, spine | 272 | $2,976 | $11 |
| Nuclear medicine study of brain with metabolic evaluation | 43 | $2,581 | $60 |
| Nuclear medicine study of bone and/or joint whole body | 72 | $2,502 | $34 |
| Nuclear medicine study of lymphatic system | 24 | $1,159 | $48 |
| Nuclear medicine study of parathyroid with spect | 26 | $1,155 | $44 |
| Nuclear medicine study of stomach to assess emptying | 11 | $367 | $33 |
2016: 16 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 295 | $30,591 | $102 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 40 | $17,528 | $438 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 40 | $6,668 | $84 |
| Dxa bone density measurement of hip, pelvis, spine | 370 | $4,115 | $11 |
| Nuclear medicine study whole body with ct scan | 32 | $3,399 | $106 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 50 | $3,393 | $68 |
| Dxa bone density measurement of hip, pelvis, spine | 51 | $2,384 | $47 |
| Nuclear medicine study of bone and/or joint whole body | 54 | $1,769 | $33 |
| Nuclear medicine study of lymphatic system | 33 | $1,697 | $51 |
| Nuclear medicine study of brain with metabolic evaluation | 13 | $799 | $61 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 17 | $662 | $39 |
| Nuclear medicine study of lung ventilation and circulation | 14 | $650 | $46 |
| Nuclear medicine study of bone and/or joint | 13 | $576 | $44 |
| Nuclear medicine study of liver and bile duct system with use of drugs | 12 | $470 | $39 |
| Nuclear medicine study of stomach to assess emptying | 14 | $436 | $31 |
| Nuclear medicine study of radioactive material distribution at sites of inflammation in whole body | 11 | $259 | $24 |
2015: 16 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 490 | $58,293 | $106 |
| Dxa bone density measurement of hip, pelvis, spine | 393 | $4,536 | $12 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 58 | $4,145 | $71 |
| Nuclear medicine study of bone and/or joint whole body | 94 | $3,527 | $35 |
| Nuclear medicine study whole body with ct scan | 31 | $3,291 | $106 |
| Nuclear medicine study of lymphatic system | 34 | $1,751 | $52 |
| Nuclear medicine study of stomach to assess emptying | 38 | $1,336 | $33 |
| Nuclear medicine study of lung ventilation and circulation | 28 | $1,288 | $46 |
| Supervision, handling, and loading of radiation source | 16 | $866 | $48 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 16 | $796 | $47 |
| Nuclear medicine study of kidney, blood, flow, and function with drug administration | 11 | $643 | $54 |
| Calculation of radiation therapy dose | 16 | $518 | $29 |
| Nuclear medicine study of bone and/or joint | 11 | $497 | $45 |
| Nuclear medicine study of bone taken at different times | 11 | $454 | $41 |
| Nuclear medicine study of radioactive material distribution at sites of inflammation in whole body | 15 | $378 | $24 |
| Nuclear medicine study of liver | 13 | $365 | $28 |
2014: 14 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 383 | $43,744 | $104 |
| Nuclear medicine study of bone and/or joint whole body | 102 | $4,045 | $35 |
| Dxa bone density measurement of hip, pelvis, spine | 256 | $2,952 | $12 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 41 | $2,665 | $65 |
| Nuclear medicine study whole body with ct scan | 14 | $1,471 | $105 |
| Nuclear medicine study of lung ventilation and circulation | 27 | $1,273 | $47 |
| Nuclear medicine study of lymphatic system | 19 | $997 | $52 |
| Nuclear medicine study of stomach to assess emptying | 31 | $992 | $32 |
| Supervision, handling, and loading of radiation source | 16 | $767 | $48 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 16 | $740 | $46 |
| Calculation of radiation therapy dose | 16 | $459 | $29 |
| Nuclear medicine study of liver | 13 | $395 | $30 |
| Nuclear medicine study of radioactive material distribution at sites of inflammation in whole body | 11 | $372 | $34 |
| Nuclear medicine study of thyroid and thyroid function | 11 | $264 | $22 |
2013: 13 services
| Nuclear medicine study from skull base to mid-thigh with ct scan | 314 | $34,209 | $98 |
| Dxa bone density measurement of hip, pelvis, spine | 265 | $2,892 | $11 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 44 | $2,653 | $60 |
| Nuclear medicine study whole body with ct scan | 25 | $2,575 | $99 |
| Nuclear medicine study of bone and/or joint whole body | 70 | $2,553 | $34 |
| Nuclear medicine study of lung ventilation and circulation | 35 | $1,596 | $46 |
| Nuclear medicine study of stomach to assess emptying | 35 | $1,097 | $30 |
| Nuclear medicine study, spect imaging, 1 area or single acquisition, single day imaging | 17 | $705 | $41 |
| Nuclear medicine study of lymphatic system | 11 | $551 | $50 |
| Supervision, handling, and loading of radiation source | 12 | $549 | $46 |
| Nuclear medicine study of whole body for thyroid cancer | 13 | $490 | $33 |
| Nuclear medicine study of kidney and blood flow | 16 | $309 | $19 |
| Calculation of radiation therapy dose | 12 | $299 | $25 |
Medicaid work
$3,022 in 2021
Medicaid paid $3,022 for 13 billed services this clinician did in 2021, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Positron emission tomography (PET) with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging; skull base to mid-thigh | 13 | $3,022 |
| 2021 | 13 | 1 | 13 | $3,022 |
Money from drug and device companies
$21 in 2024
| 2024 | 1 | 1 | None | $21 |
| 2023 | 2 | 2 | None | $139 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Progenics Pharmaceuticals | Pylarify | $21 | 1 payment
|
See the published payment
| Progenics Pharmaceuticals | Meals · 2024-07-09 | Pylarify | $21 |
See earlier years (2023)
2023: $139
| Pfizer | Vyndaqel | $80 | 1 payment
|
| Genentech USA | Hemlibra | $59 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 96.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1356404180
- Licence
- CA A70244California A70244: Current · expires 2027-11-30
- Trained
- University of Texas Southwestern Medical School at Dallas, 1998
- Group
- Regents of the University of California · The Regents of the University of California
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A702440
- Taxonomy
- Diagnostic radiology (2085R0202X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-12-19
- NPI last updated
- 2010-01-13
This is when the NPI record was last certified, not a medical board exam.